Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma

PURPOSE: Autologous chimeric antigen receptor (CAR) T cell therapy is one of the most significant breakthroughs in hematological malignancies. However, a three-week manufacturing cycle and ineffective T cell dysfunction in some patients hinder the widespread application of auto-CAR T cell therapy. S...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Tiantian, Luo, Cancan, Zhang, Huihui, Tan, Yi, Yu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338183/
https://www.ncbi.nlm.nih.gov/pubmed/37449207
http://dx.doi.org/10.3389/fimmu.2023.1139482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338183/
https://www.ncbi.nlm.nih.gov/pubmed/37449207
http://dx.doi.org/10.3389/fimmu.2023.1139482

Ejemplares similares